Friday, February 26, 2021
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Articles
    • See All Articles
    • NEW: COVID-Related
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Leadership and Career
  • Vendor News
  • Jobs
    • Compliance & Risk
    • Information Security
  • Events
    • Webinars & Events
    • Submit an Event
  • Downloads
    • eBooks
    • Whitepapers
  • Podcasts
  • Videos
  • Subscribe
No Result
View All Result
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Articles
    • See All Articles
    • NEW: COVID-Related
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Leadership and Career
  • Vendor News
  • Jobs
    • Compliance & Risk
    • Information Security
  • Events
    • Webinars & Events
    • Submit an Event
  • Downloads
    • eBooks
    • Whitepapers
  • Podcasts
  • Videos
  • Subscribe
No Result
View All Result
Corporate Compliance Insights
Home GRC Vendor News

GlaxoSmithKline Encounters Initial Resistance Following Directional Shift, says GlobalData Analyst

by Corporate Compliance Insights
February 10, 2015
in GRC Vendor News

LONDON, UK (GlobalData), 10 February 2015 – Following a less than flattering financial performance in 2014, GlaxoSmithKline plc (GSK) is realigning its operating structure with its corporate objectives and cashing in on its assets in the process, as the company seeks to drive up external investments and deliver stronger shareholder returns in the long term, says an analyst with research and consulting firm GlobalData.

Excluding divestments, GSK’s total revenue fell by 10% year-on-year while operating profits were down by 15% on a pro forma basis in 2014. While the growing strength of the pound sterling was largely to blame for lower revenues through the first three quarters of the year, a large proportion of the company’s decline was inorganic.

Chloe Thornton, MSc, GlobalData’s Company Analyst, states that within its central pharmaceuticals business, GSK’s greatest growth resistor was by far its flagship respiratory franchise, which fell by 10% year-on-year to just over £6 billion ($9.8 billion), excluding currency impacts.

Thornton explains: “GSK invested heavily in developing its respiratory pipeline, but the expectation that it could compensate for the imminent patent cliff facing Seretide/Advair appears optimistic.

“Sales of Breo Ellipta came to £67 million ($106 million), while Anoro earned just £17 million ($27 million) in 2014, well short of GSK’s estimates.”

In addition, a further 26 pharmaceutical products witnessed year-on-year declines through 2014, at a total loss of £1.2 billion ($1.9 billion).

The analyst notes that despite the strong performance of GSK’s cancer therapeutics business, the company has agreed to divest its oncology assets to Novartis, while GSK is also considering divesting a share of its stake in its other best performing business, the ViiV Healthcare joint venture.

Thornton continues: “The strength of GSK’s oncology portfolio against a backdrop of decline elsewhere across its pharma business somewhat calls into question the decision to trade these assets to Novartis.

“However, the $16 billion capital boost GSK will derive from the deal when it is completed over the next few months should help to dispel those concerns, provided the company can proactively invest this capital in areas of high growth potential.”


Previous Post

Cybersecurity Concerns Rise as a Risk Factor for Board Members and Senior Executives in 2015

Next Post

Judicial Oversight of Deferred Prosecution Agreements

Corporate Compliance Insights

Related Posts

red paper plane breaking rank from white paper planes

Diligent to Become Largest Global GRC SaaS Company Through Galvanize Acquisition

February 24, 2021
gold cup award on red background with stars

Ethisphere Announces the 2021 World’s Most Ethical Companies

February 23, 2021
hands fitting puzzle pieces together on yellow background

LexisNexis® Risk Solutions and Accuity Join Operations

February 18, 2021
concept next generation technology

NICE Launches Next-Gen Compliance Solution

February 1, 2021
Next Post
Judicial Oversight of Deferred Prosecution Agreements

Judicial Oversight of Deferred Prosecution Agreements

Access realtime data
Addressing systemic racism in the workplace SAI Global
Dynamic Risk Assessments with Workiva
Top 10 Risk and Compliance Trends

Special Coverage

Special COVID page graphic

Jump to a Topic:

anti-corruption anti-money laundering/AML Artificial Intelligence/A.I. automation banks board of directors board risk oversight bribery CCPA/California Consumer Privacy Act Cloud Compliance communications management Coronavirus/COVID-19 corporate culture crisis management cyber crime cyber risk data analytics data breach data governance decision-making diversity DOJ due diligence fcpa enforcement actions financial crime GDPR GRC HIPAA information security KYC/know your customer machine learning monitoring ransomware regtech reputation risk risk assessment Sanctions SEC social media risk supply chain technology third party risk management tone at the top training whistleblowing
No Result
View All Result

Privacy Policy

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • RSS Feed

Category

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • Opinion
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Whitepapers

© 2019 Corporate Compliance Insights

No Result
View All Result
  • Home
  • About
  • Articles
  • Vendor News
  • Podcasts
  • Videos
  • Whitepapers
  • eBooks
  • Events
  • Jobs
  • Subscribe

© 2019 Corporate Compliance Insights